Biotechnology

Thursday Mar 31, 2022 - 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Reiterates Commitment to Operational Excellence, Advancing Berubicin Recognition

In a video message to shareholders, CEO John Climaco detailed the operational and clinical progress made by lead drug candidate Berubicin despite market volatility and share price fluctuationsCNS is currently enrolling patients into a potentially pivotal global drug trial of Berubicin for recurrent glioblastoma multiformeInterim analysis of the trial is currently expected as early as the first quarter of 2023, once 30-50% of trial patients…

Tuesday Mar 29, 2022 - 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Update on Advances in Brain Cancer Drugs and Operational Financials

Texas-based CNS Pharmaceuticals is a novel brain cancer drug developer that is building a series of global clinical trials for its lead drug candidate, BerubicinCNS began dosing patients in a global trial last September to evaluate Berubicin in treating glioblastoma multiforme (“GBM”), currently an incurable brain cancerCNS received FDA Fast Track designation for Berubicin in June 2021 and FDA Orphan Drug designation for Berubicin in…

Monday Mar 28, 2022 - 9:00 am

Psychedelic Medicine Researcher Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Readies IND Application to Advance Drug Trials

Novel drug development company Mydecine Innovations Group is focusing on a medicinal pipeline for psychedelic drug candidates that have established some efficacy in treating mental illnesses — specifically addictionMydecine is progressing in its clinical trial evaluation of its lead candidate, MYCO-001, and is finalizing an IND application with the FDA to begin patient dosing for its planned Phase 2 trialsThe company is targeting nicotine addiction…

Thursday Mar 24, 2022 - 9:15 am

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Is a Leader in Psychedelic-Based Therapies; Recent Preclinical Research Shows Treatment Effective for MDD

Study shows that substantial antidepressant effects of psilocybin-based treatment, given with supportive psychotherapy, may last at least a year.Psilocybin could lead to significant, durable improvements in depression.Cybin is focused on improving overall mental health through psychedelic-based therapies. Johns Hopkins Medicine researchers have released a report noting that psilocybin treatment for major depression is effective for up to a year for many patients (https://ibn.fm/ZF8jH). That bodes…

Thursday Mar 17, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) on Leading Edge of Development of Psychedelics as Public Support Grows

More than 60% of American who suffer from mental health conditions want access to psychedelic optionsGrowing number of cities, states looking at decriminalizing use of psychedelic medicineCybin is working with world-class partners, internationally recognized scientists to create safe, effective therapeutics in the mental-health space The awareness of psychedelics and the potential for treating an array of mental health diseases is growing, as evidenced by a…

Thursday Mar 17, 2022 - 9:00 am

Metabolic Health Diseases Rising Globally, Nemaura Medical Inc. (NASDAQ: NMRD) Aims to Disrupt Market with Non-Invasive, Cost-Effective IoT Devices, Mikobo Coaching Program

Metabolic disease cases rising globally, diseases include diabetes, dementia, cardiovascular conditions, strokeCompanies in diagnostic space posting record revenues, double-digit YOY increasesNemaura Medical aims to disrupt the market with Mikobo program’s non-invasive sensor technology, companion mobile application and coaching programsCompetitor devices use microneedles coated with enzymes and polymers that can cause discomfort, trauma, and skin changes Clinical research reveals that volatile blood sugar fluctuations are a…

Thursday Mar 03, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted U.S. Patent for Deuterated DMT

Company announced the first officially issued patentPatent provides strong protection for Cybin’s growing IP portfolio of psychedelic-based compoundsCYB004 has demonstrated potential efficacy at lower doses while increasing duration of drug effect that may alleviate common negative experiences In a milestone moment for psychedelic therapeutics company Cybin (NEO: CYBN) (NYSE American: CYBN), the company has announced its first official issued patent. The U.S. Patent and Trademark Office…

Wednesday Mar 02, 2022 - 9:15 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) and BayMedica Rare Cannabinoids to Enter Market Q1 2022; Leveraging on Fast-Growing Global Health and Wellness Market

Over 140 rare cannabinoids exist in the cannabis plant – some with the potential to have more therapeutic benefits than those cannabinoids found prominently in the plantInMed and subsidiary BayMedica plan to release several rare cannabinoid products in the first half of 2022 Combination of complementary InMed and BayMedica business models key to increasing shareholders’ value In 2020, the global health and wellness market reached $4.436…

Wednesday Mar 02, 2022 - 9:00 am

Nemaura Medical Inc.’s (NASDAQ: NMRD) sugarBEAT(R) Wearable CGM Device Targets Billion-Dollar Global Diabetes Market

Global diabetes-related healthcare expenses are estimated at $966 billion in 2021A recent report reveals 537 million adults currently live with diabetes, projected to rise to 643 million by 2030 and 783 million by 2045 Glucose intake is an important factor in diabetes management, prevention and reversalNMRD’s sugarBEAT(R) wearable is a non-invasive, flexible CGM device helping diabetes and prediabetes patients monitor glucose levelsNMRD’s MiBoKo metabolic health program…

Monday Feb 28, 2022 - 9:15 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Makes Exciting Drug Discovery for the Treatment of Mental health and Addiction Disorders – MYCO-005

Mydecine announced the inclusion of a patent-pending novel molecule in its family of psilocin analogs, MYCO-005This molecule features potentially heart-safe microdose-enabling properties, addressing the delivery and stability concerns associated with the first-generation compoundsMydecine’s patent-pending dermal route to administration also offers more control over the drug while possibly eliminating undesirable properties such as nauseaThe company is excited about this finding, terming it one of the many…

Wednesday Feb 23, 2022 - 10:15 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Communicating the Therapeutic Benefits of Psychedelics; Advocating for Accurate and Consistent Messaging to Promote The Acceptance of Psychedelics in Therapeutics

Studies suggest that psychedelics such as psilocybin and MDMA offer health benefits when used to treat patients with depression and PTSDThese results have encouraged scientists, psychotherapists, and entrepreneurs, who say that FDA approvals may be on the horizonMydecine is playing a vital role in pushing the knowledge of the benefits of psychedelic compounds by undertaking clinical research in partnership with academicsIn a recent interview, company…

Tuesday Feb 22, 2022 - 9:30 am

AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) Is ‘One to Watch’

In the first quarter of 2022, AREV acquired Wright & Well Essentials Inc., a firm with an extensive hemp and cannabis line of branded products currently sold in Oregon and expanding markets.The company’s online sales and marketing platform, Medicine Merchant™, is in the final stages of development; the platform has the potential to revolutionize consumer access to therapeutic interventions and personalized medicine via partnerships with…

Thursday Feb 17, 2022 - 1:12 pm

Nemaura Medical Inc. (NASDAQ: NMRD) Seeks to Provide Non-Invasive Glucose Monitoring Solutions to Millions of Patients Worldwide

Over 420 million people around the globe currently have diabetes, with the figure set to rise by 55% over the next 25 yearsMillions of patients required to measure their blood glucose levels daily to accurately determine their insulin dosage amountsNemaura Medical has launched two constant glucose monitoring solutions – the SugarBEAT(R) device as well as the MiBoKo application, which seek to provide users with a…

Tuesday Feb 15, 2022 - 9:30 am

Identified Psilocybin and MDMA Supplier, New Addition Strengthens Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Board Experience

Biotechnology company Mydecine Innovations Group is devoted to advancing the use of psychedelics for the treatment of mental illnesses and addictionMydecine has necessary license to provide psilocybin and MDMA under Canada’s SAP program, which allows medical providers to request otherwise unavailable drug substances for the treatment of patients who have not seen success with available treatment optionsThe license allows Mydecine to provide psilocybin and MDMA…

Monday Feb 14, 2022 - 9:30 am

Nemaura Medical Inc.’s (NASDAQ: NMRD) CEO Dr. Faz Chowdhury Addresses Growing CGM Demand at H.C. Wainwright BioConnect Conference

NMRD CEO Dr. Faz Chowdhury presented at H.C. Wainwright BioConnect Conference held January 10-13, 2022Presentation revealed growing need for CGM devices, diabetes market estimated at $150 billionNMRD's sugarBEAT(R) devices measure glucose at the skin surface, non-invasive, easy to useNMRD recently commenced product shipments in lieu of an order for 5,000 CGM devices and 200,000 sensors to UK licensing partner MySugarWatch LimitedNMRD recently announced launch of…

Monday Feb 14, 2022 - 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives IRB Approval for Kernel Flow Feasibility Study

Institution Review Board gives green light to study designed around Kernel’s quantitative neuroimaging technologyKernel Flow device provides ability to measure longitudinal brain activity before, during and after a psychedelic experienceCYBN CEO says results from study will further support company’s mission to develop psychedelics into therapeutics Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received approval to move forward…

Wednesday Feb 09, 2022 - 9:00 am

Nemaura Medical Inc. (NASDAQ: NMRD) Set to Capitalize on Glucose Monitoring Sector’s Exponential Growth Rate

The blood glucose monitoring system sector is expected to grow to a value of $27.2 billion by 2026, expanding at a CAGR of 9.6% between 2021-2026Over 420 million people around the globe currently have diabetes, with the American Diabetes Association recommending that all adults screen for the condition every three yearsNemaura Medical has sought to capitalize on the blood glucose monitoring sector’s phenomenal growth rate…

Thursday Feb 03, 2022 - 10:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Strengthens Leading Role in Rare Cannabinoid Market Following New Product Launch, Key Acquisition

Cannabicitran is the first of four new rare cannabinoids InMed is planning to launch in the first half of the year to meet growing inbound demandThe launch demonstrates InMed’s ability to produce rare cannabinoids at scale, something only very few companies have achievedBayMedica acquisition, other key achievements in 2021, are positioning the company as a leading supplier of rare cannabinoids in the health and wellness…

Wednesday Feb 02, 2022 - 12:38 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Clinical LOI to Further Use of Psychedelic Therapeutics in Treating Mental Illnesses

Canadian-based mental health treatment-focused biotechnology company Mydecine Innovations Group has been advancing research on the use and improvement of compounds found in nature, particularly the psychedelic psilocybin compoundMydecine recently announced an LOI with The Newly Institute to use Mydecine’s psilocybin and MDMA for treatment at The Newly’s mental health clinics nationwideThe LOI is the first collaboration under Mydecine’s SASSP program, which will provide psychedelic drug…

Monday Jan 31, 2022 - 1:03 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Could ‘Lead to New Frontiers,’ Begins Enrollment This Year

Upcoming study supports CYBN’s mission to develop psychedelics into therapeutics.Kernel Flow uses pulsed light instead of continuous wave light to increase measured brain information. Study may provide crucial “mind-imaging” information that has been previously missing. Cybin (NEO: CYBN) (NYSE American: CYBN) is starting off the new year right — the company has received approval from an Institutional Review Board (“IRB”) for a feasibility study using Kernel’s quantitative…

Friday Jan 28, 2022 - 11:00 am

Nemaura Medical Inc. (NASDAQ: NMRD) Appoints Technical Healthcare Specialist Dr. Arash Ghadar as COO

NMRD appoints UK-based Dr. Arash Ghadar as Chief Operating Officer, brings decades of healthcare and technology experienceDr. Ghadar previously supervised product development lifecycles, feasibility studies, prototyping, validation, quality management, volume manufacturing, certificationNMRD commercializing sugarBEAT(R) non-invasive, flexible, CGM device, recently completed initial shipment to UK licensee MySugarWatch LimitedMySugarWatch Limited aims to market devices via subscription-based diabetes coaching and management service Nemaura Medical (NASDAQ: NMRD), a medical…

Thursday Jan 27, 2022 - 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Company’s Position in Emerging Wellness Trend

Psychedelics pose potential as effective treatments for mental-health issues such as depression, anxiety, and substance abuseWell+Good says psychedelics “poised to change the course of mental health treatment”Cybin working to combine novel psychedelic molecules with controllable drug-delivery systems through proprietary deuterated process A USA Today article is touting psychedelics as the next big thing in mental health treatment (https://ibn.fm/3ZGGE). This forecast aligns perfectly with what Cybin (NEO: CYBN) (NYSE…

Wednesday Jan 26, 2022 - 12:15 pm

InMed Pharmaceuticals Inc. (NASDAQ: INM) Leveraging on the Growing Cannabinoid-Based Pharmaceuticals Market

The global cannabinoid-based pharmaceuticals market is projected to be valued at $50 billion by 2029InMed is leading the industry, laying down the foundation in manufacturing and clinical development of rare cannabinoidsIt is shedding light on the potential of rare cannabinoids and laying the groundwork on how to tap into the industry’s growth It is projected that by 2025, the global cannabis market will be valued…

Tuesday Jan 25, 2022 - 11:15 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Marks Significant Milestone in Pursuit of Berubicin Approval for Global GBM Treatment, Raises $11.5 Million from Private Placement

CNS Pharmaceuticals received approval from swissethics for its potentially pivotal study of Berubicin, a novel anthracycline for the treatment of Glioblastoma Multiforme (“GBM”)The approval is the first from a European Ethics CommitteeThe company, which dosed the first patients in its Berubicin program in September, has selected multiple clinical sites across the U.S., Spain, France, Italy, and SwitzerlandCNS recently closed an $11.5 million private placementIt intends…

Monday Jan 24, 2022 - 1:20 pm

Nemaura Medical Inc. (NASDAQ: NMRD) Commence Rollout of Their Miboko Application; Company Targets Employers & Insurers to Ensure Broad Commercial Distribution

Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devicesThe company recently announced the rollout of its Miboko application by targeting insurers and employersIn 2019, over $760 billion was spent on diabetes-related health care, equating to $9,000 per diabetic patient compared to $1,600 for a non-diabetic individualThe Miboko application provides users with an efficient and accurate means of tracking their day-to-day…

Monday Jan 24, 2022 - 12:28 pm

Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Plans Program to Provide Resources for Safe, Effective Integration of Psychedelic-Assisted Psychotherapies into Existing Medical Practices

Mydecine plans to launch a program to provide products and services to healthcare professionals, clinics, and hospitals in Canada looking to treat patients through psychedelic-assisted psychotherapyThe products and services, which will be available for purchase as a package, include cGMP psilocybin and MDMA, therapy manuals, investigative brochures, protocol training, advisory services, and post-therapy supportThe planned launch follows an amendment to federal regulations allowing physicians to…

Thursday Jan 20, 2022 - 1:19 pm

Nemaura Medical Inc. (NASDAQ: NMRD) Firmly Positioned in Growing Diabetes Tech Market With Recent CGM Shipment to UK Licensee

Diabetes tech market expanded in 2021 due to new users, growing demand for CGM devices, coverage of CGM devices by CMS Diabetes is a growing problem in the US. According to CDC, roughly 1 in 10 Americans have diabetes, and 1 in 3 have pre-diabetesNMRD currently commercializing the sugarBEAT(R) non-invasive and flexible continuous glucose monitorCompany recently completed initial shipment to UK licensee While most medical technology…

Wednesday Jan 19, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Emerging as Psychedelics Leader, Looking Forward to ‘Transformative’ Year

Company marked host of major milestones and accomplishments in 2021Approvals, licenses, expansions and growth all essential pieces of Cybin successCYBN’s innovative operational and R&D pipeline platforms expected to support four first-in-human clinical studies in 2022 As the new year begins, Cybin (NEO: CYBN) (NYSE American: CYBN) couldn’t be in a better position. The biopharmaceutical company’s commitment to establishing a stronghold in the psychedelics space paid off…

Wednesday Jan 19, 2022 - 9:00 am

Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) CEO Shares Company Success Insights on Bell2Bell Podcast

Mr. Josh Bartch, the CEO, Chairman, and Co-Founder of Mydecine, attributed the company’s success to its phased approach to product research and developmentHe noted significant strides in smoking cessation and PTSD research over the 2021 calendar year, which will be integral to operations in the new yearMr. Bartch was also proud of the current efficacy data around psilocybin to treat nicotine dependance which is significantly…

Wednesday Jan 12, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes ‘Milestone’ Step with USPTO Notice of Allowance CYB004

Cybin awarded notice for company’s innovative treatment of anxiety disordersApproval demonstrates company’s dedication to discovery and development of psychedelic-based compounds for addressing mental healthAnxiety disorders rank among the most common mental illnesses in the country Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its strategic plan to strengthen its position as leading innovator in developing putative psychedelic compounds. The company has received…

Monday Jan 10, 2022 - 12:19 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Announces Completion of Target-Based Model in Its AI-Driven Drug Discovery Program

The AI-driven drug discovery program uses not only artificial intelligence but also machine learning, which is a relatively new concept and is continuously expandingThe use of artificial intelligence in the drug development space may help eliminate or reduce the manual operations that a company typically must undergo to identify and make necessary improvements to drugs The new model will allow the company to rapidly screen billions…

Monday Jan 10, 2022 - 10:22 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Participation in Upcoming Events Recognizes Company Expertise

CEO to participate in panel discussion, fireside chat focusing on psychedelicsThe company is engineering next-generation psychedelic molecules as it works to transform the mental health treatment landscapeCYBN is implementing a three-pillar strategy Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is gaining recognition as a leader in the psychedelic space. Evidence of this can be seen in the Cybin…

Thursday Jan 06, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key Meeting with UK Regulatory Agency

Meeting takes company a step closer to advancing its lead investigational candidate CYB003 into clinical developmentCYB003 is designed for the treatment of two significant conditions: major depressive disorder (“MDD”) and alcohol use disorder (“AUD”)CEO notes that CYB003 has the potential to achieve better patient outcomes The coming year holds significant promise for Cybin (NEO: CYBN) (NYSE American: CYBN) for numerous reasons. The biopharmaceutical company has seen…

Wednesday Jan 05, 2022 - 11:47 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Entering 2022 With Multiple Clinical Trials Including MYCO-001 for Smoking Cessation

Mydecine has partnered with Dr. Matthew Johnson and Johns Hopkins University for two upcoming trials for MYCO-001 – a psilocybin approach to smoking cessationThe company is positioned to fill a billion-dollar hole in the industry after the leading pharmaceutical Chantix was removed from the market due to cancer risksTwo previous psilocybin trials conducted by Dr. Johnson, show promising results for the use of psilocybin as…

Tuesday Jan 04, 2022 - 10:32 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Milestone Notice of Allowance for Revolutionary Treatment of Anxiety Disorders

USPTO notice marks important milestone in the expansion of CYBN’s intellectual property portfolioOnce issued, patent may have opportunity to cover a broad range of claimsAnxiety disorders are one of the most common mental illnesses in the United States Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its commitment to progressing Psychedelics to Therapeutics(TM). The biopharmaceutical company has received a notice of allowance…

Thursday Dec 30, 2021 - 9:00 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Inches Closer to iSTRYM’s Commercial Deployment; Announces Dr. Doron Sagman’s Appointment as CMO; and Avails Recent Life Sciences Virtual Conference Presentation for On-Demand Viewing

MINDCURE just announced receiving its HIPAA certification for iSTRYM, its AI-powered, SaaS platform for psychedelic therapyThis marks a key milestone for the company, having already exceeded its target of 10 partner clinics by the end of 2021It also inches the company closer to the platform’s commercial deployment, set for the second quarter of 2022This comes just in time, following the appointment of Dr. Doron Sagman…

Monday Dec 27, 2021 - 11:14 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Recognized as One of the Best Women-Led Workplaces, Participates in the December 16 Life Sciences Virtual Investor Conference

The Great Place to Work organization included MINDCURE in its 2021 list of the Best Workplaces Managed by WomenThe company was recognized for its employee-oriented perks and programs, which include flexible working hours, monthly team-building events, and a remote work office stipendMINDCURE also participated in the Life Sciences Virtual Investor Conference held on December 16, where executives shared the company’s corporate vision and fielded questions…

Wednesday Dec 22, 2021 - 12:37 pm

Nemaura Medical Inc. (NASDAQ: NMRD) Complete Initial Shipment of sugarBEAT(R) Devices to UK Licensee

Nemaura Medical announced the successful completion of its initial shipment of sugarBEAT(R) continuous glucose monitor devices to its UK licenseeThe initial shipment, which comprised 5,000 CGM devices and 200,000 sensors, is expected to result in follow-on monthly orders of up to 2 million sensors and 15,000 CGM devices over the next two yearsFollowing the launch of the sugarBeat(R), Nemaura Medical have released the MiBoKo application,…

Monday Dec 20, 2021 - 12:11 pm

RYAH Group Inc. (CSE: RYAH) Releases Medical Cannabis Report on Cancer and Adverse Cancer Treatment Effects

RYAH recently released report highlighting medical cannabis treatment for cancer and adverse effects of cancer treatmentData from 80,000 sessions logged between January 1, 2018 and November 15, 2021 tracked conditions including anxiety, cachexia, fatigue, pain, nausea, and stress62% of patients reported a moderate experience using cannabis to treat cancer-related conditionsRYAH supports cancer research and treatment with IoT product ecosystem comprised of volume-control devices, medicine-carrying components,…

Monday Dec 20, 2021 - 11:50 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), an Undervalued Opportunity for Investment

Mydecine’s and CMPS’ stocks have been grossly undervalued largely due to a lack of understanding of the psychedelic space The situation presents a unique opportunity for investment, as Roth Capital Partners issued a $3 buy rating for 2022Mydecine has put systems and infrastructure in place to bank on the growing PTSD treatment, smoking cessation, and the health and wellness apps market, in its drive to increase…

Articles

Articles Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions